Nikolai V. Naoumov

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

51h-index10.6kcitations165works5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(117), Hepatitis B Virus Studies(110), Liver Disease Diagnosis and Treatment(68), Hepatitis Viruses Studies and Epidemiology(16), Viral gastroenteritis research and epidemiology(11)

Publications165 total

Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis
Alimentary Pharmacology & Therapeutics·2025· 2 citedOpen Access
Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy
JHEP Reports·2025Open Access
THU-445 Subgroup definition and monitoring of liver fibrosis evolution in patients with MASH bridging fibrosis based on objective measurements of septa parameters using digital pathology with artificial intelligence analyses
Journal of Hepatology·2025
Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology
Liver International·2024· 6 citedOpen Access
IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab
Clinical Gastroenterology and Hepatology·2024· 16 citedOpen Access
Second harmonic generation digital pathology with artificial intelligence: breakthroughs in studying fibrosis dynamics and treatment response
Future Medicine AI·2024· 1 citedOpen Access
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy
Gut·2024· 21 cited
FRI-203 Validation of optimal liver biopsy size for reliable quantitation of fibrosis severity in different areas and structures of liver lobule using second harmonic generation microscopy with artificial intelligence analyses
Journal of Hepatology·2024· 1 cited
A deep exploration of bridging fibrosis evolution and individual septa parameters in NASH using quantitative second harmonic generation imaging reveals fibrosis changes in natural history and treatment-induced not seen with conventional histology
Journal of Hepatology·2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Hepatology·2023· 58 citedOpen Access
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Nature Medicine·2023· 147 citedOpen Access
Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)
Journal of Hepatology·2022· 12 cited
Magnetic resonance elastography (MRE) demonstrate the strongest correlation with digital pathology and NASH CRN fibrosis assessments, compared to transient elastography and other assessed non-invasive tests (NITs)
Journal of Hepatology·2022· 2 cited
Second harmonic generation microscopy can quantify and subclassify early stages of NASH fibrosis progression: data from a screen-failure cohort of a NASH phase 2 study
Journal of Hepatology·2022
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
Journal of Hepatology·2022· 102 citedOpen Access
Hepatitis viruses (excluding hepatitis C virus)
2020
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic <scp>HCV</scp> genotype 1 infection (<scp>ESSENTIAL II</scp>)
Alimentary Pharmacology & Therapeutics·2015· 41 citedOpen Access
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B
Advances in Therapy·2015· 22 citedOpen Access
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
Hepatology·2015· 51 cited
Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
Gastroenterology·2014· 57 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Roger Williams(9), Shilpa Chokshi(9), Edward Gane(8), Roger Williams(8), Bernard Portmann(7), Jinlin Hou(5), Yun‐Fan Liaw(4), Stefan Zeuzem(4), P. Carucci(4), S M Phillips(4), Antonio Riva(4), Roger Williams(4), Zachary Goodman(3), Michael P. Manns(3), Helen Cooksley(3), Matthew Cramp(3), S. Rossol(3), Mark Thomas(3), Seng Gee Lim(3), George Marinos(3)